Shares of Phio Pharmaceuticals Corp. (PHIO) are surging more than 90% in premarket trading today.
Phio Pharma is a clinical-stage biotech company developing therapeutics using its proprietary INTASYL siRNA gene silencing technology. This self-delivering RNAi platform enhances immune cells to more effectively target and kill cancer cells.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com